Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting

The immunosuppressive agent leflunomide has been used in the treatment of over 300,000 patients with rheumatoid arthritis. Its active metabolite, teriflunomide (Ter), directly inhibits dihydroorotate dehydrogenase (DHODH), an enzyme involved in nucleoside synthesis. We report that Ter not only shows...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Ther Oncolytics
Asıl Yazarlar: Buettner, Ralf, Morales, Corey, Wu, Xiwei, Sanchez, James F., Li, Hongzhi, Melstrom, Laleh G., Rosen, Steven T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Gene & Cell Therapy 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6562366/
https://ncbi.nlm.nih.gov/pubmed/31211245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2019.04.006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller